RAGE ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression.

ABSTRACT:

Background

Malignant gliomas consist of heterogeneous cellular components that have adopted multiple overlapping escape mechanisms that overcome both targeted and immune-based therapies. The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily that is activated by diverse proinflammatory ligands present in the tumor microenvironment. Activation of RAGE by its ligands stimulates multiple signaling pathways that are important in tumor growth and invasion. However, treatment strategies that only target the interaction of RAGE with its ligands are ineffective as cancer therapies due to the abundance and diversity of exogenous RAGE ligands in gliomas.

Methods

As an alternative approach to RAGE ligand inhibition, we evaluated the geneti

SUBMITTER: Zhang IY 

PROVIDER: S-EPMC10158202 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature